Insider · CIK 0001420822

Lanfear Dennis M

Reports to the SEC for 2 companies · REDWOOD CITY, CA

sec.gov

Transactions

Companies

Filings

CIK

0001420822

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−200K sh	—	—	0
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−400K sh	—	—	0
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−450K sh	—	—	0
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−500K sh	—	—	0
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−500K sh	—	—	0
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−125K sh	—	—	0
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−403K sh	—	—	0
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−403K sh	—	—	0
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−225K sh	—	—	0
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+200K sh	—	—	200,000
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+400K sh	—	—	400,000
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+450K sh	—	—	450,000
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+500K sh	—	—	500,000
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+500K sh	—	—	500,000
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+125K sh	—	—	125,000
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+403K sh	—	—	402,500
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+403K sh	—	—	402,500
2026-05-29	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+225K sh	—	—	225,000
2026-01-23	CHRSCoherus Oncology, Inc.A Award	Director, President & CEO	AAward	+375K sh	—	—	1,048,235
2026-01-23	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+750K sh	—	—	750,000
2026-01-20	CHRSCoherus Oncology, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−11.8K sh	$1.55	−$18.4K	673,235
2025-05-07	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+375K sh	—	—	375,000
2025-01-20	CHRSCoherus Oncology, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−11.8K sh	$1.39	−$16.4K	685,074
2025-01-10	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+575K sh	—	—	575,000
2025-01-04	CHRSCoherus Oncology, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−11.8K sh	$1.66	−$19.6K	696,884
2024-07-22	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+197K sh	—	—	196,500
2024-01-20	CHRSCoherus Oncology, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−11.2K sh	$2.44	−$27.4K	708,694
2024-01-05	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+575K sh	—	—	575,000
2024-01-04	CHRSCoherus Oncology, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−11.8K sh	$2.92	−$34.4K	719,912
2023-11-22	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+41K sh	$1.42	+$58.1K	695,853
2023-11-22	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+259K sh	$1.42	+$367K	954,793
2023-11-22	CHRSCoherus Oncology, Inc.S Sale	Director, President & CEO	SSale	−223K sh	$2.02	−$450K	731,693
2023-11-22	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−300K sh	—	—	0
2023-06-13	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+225K sh	—	—	225,000
2023-01-20	CHRSCoherus Oncology, Inc.A Award	Director, President & CEO	AAward	+86.3K sh	—	—	654,853
2023-01-05	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+403K sh	—	—	402,500
2023-01-04	CHRSCoherus Oncology, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−10.9K sh	$9.87	−$108K	568,603
2022-12-30	CHRSCoherus Oncology, Inc.G Gift	Director, President & CEO	GGift	−4,000 sh	—	—	432,684
2022-01-04	CHRSCoherus Oncology, Inc.A Award	Director, President & CEO	AAward	+86.3K sh	—	—	579,508
2022-01-04	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+403K sh	—	—	402,500
2021-11-17	CHRSCoherus Oncology, Inc.G Gift	Director, President & CEO	GGift	−10K sh	—	—	436,684
2021-06-08	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+31.1K sh	$0.42	+$12.9K	524,312
2021-06-08	CHRSCoherus Oncology, Inc.S Sale	Director, President & CEO	SSale	−31.1K sh	$13.56	−$421K	493,258
2021-06-08	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−31.1K sh	—	—	0
2021-06-06	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+300K sh	$0.42	+$125K	493,258
2021-06-06	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−300K sh	—	—	31,054
2021-02-01	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+125K sh	—	—	125,000
2021-01-23	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+500K sh	—	—	500,000
2020-07-01	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+30K sh	$0.01	+$248.95	193,258
2020-07-01	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−30K sh	—	—	0

Recent filings

Accepted (ET)
Jun 24
Lanfear Dennis M0001104659-26-069621
SEC(opens sec.gov)
Jan 264
Lanfear Dennis M0001610717-26-000027
SEC(opens sec.gov)

Companies

Address

C/O COHERUS ONCOLOGY, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600

REDWOOD CITY, CA, 94065